Reintroducing
About us / Press room
News about our community
Our actions match our words
July 29, 2021
ORTHO DERMATOLOGICS ANNOUNCES 2021 ASPIRE HIGHER SCHOLARSHIP RECIPIENTS
Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

RALEIGH, N.C., July 29, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2021 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship up to $10,000 to pursue their undergraduate or graduate degrees.

“For nine years, Ortho Dermatologics has supported students in achieving their higher education goals through our Aspire Higher scholarship program. Beyond the demands of their schooling and extracurricular activities, these students have also had to manage the burden of living with a skin condition,” said Scott Hirsch, senior vice president and chief strategy officer, Bausch Health, and president, Ortho Dermatologics. “The stories our 2021 scholarship recipients shared with us are inspiring, and we are honored to provide them with this award to recognize their achievements and help them pursue their academic aspirations.”
April 27, 2021
ORTHO DERMATOLOGICS ANNOUNCES STATISTICALLY SIGNIFICANT TOPLINE RESULTS FROM SECOND PIVOTAL PHASE 3 CLINICAL TRIAL EVALUATING IDP-126 GEL IN ACNE VULGARIS
All Three Co-Primary Endpoints Were Achieved

RALEIGH, N.C., April 27, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating its investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical, to treat acne vulgaris in patients nine years of age and older. If approved, IDP-126 would be the first-in-class with this triple combination.

Acne is the most common skin problem in the United States, affecting up to 50 million Americans.1,2
April 21, 2021
ORTHO DERMATOLOGICS TO PRESENT NEW DATA AT THE AAD VMX 2021, VIRTUAL MEETING EXPERIENCE
Six Poster Presentations Include New Analyses of ARAZLO®, DUOBRII® and SILIQ®

RALEIGH, N.C., April 21, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of six posters during the AAD VMX 2021, Virtual Meeting Experience, which takes place April 23-25, 2021.

One presentation will feature new analyses of ARAZLO® (tazarotene) Lotion, 0.045%, including new topline efficacy results from a post hoc analysis of Phase 3 studies on participants with moderate-to-severe acne. Approved for patients nine years or older, ARAZLO has been commercially available since 2020. Two other presentations will highlight DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%. With 4 in 5 patients surveyed feeling that their current treatments are not effective enough, one of the DUOBRII posters will provide an overview of the profound effect of psoriasis on quality of life for patients, while both will include new efficacy data. The three remaining presentations will include analyses evaluating the long-term efficacy and safety profile of SILIQ® (brodalumab) Injection.  Please see below for warning about suicidal ideation and behavior with SILIQ.
February 2, 2021
ORTHO DERMATOLOGICS ANNOUNCES 2021 ASPIRE HIGHER SCHOLARSHIP PROGRAM
Students Living with Dermatologic Conditions Are Encouraged To Apply Through May 31, 2021

RALEIGH, N.C., Feb. 2, 2021 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals.
October 26, 2020
ORTHO DERMATOLOGICS TO PRESENT NEW ANALYSES AT THE VIRTUAL FALL CLINICAL DERMATOLOGY CONFERENCE
RALEIGH, N.C., Oct. 26, 2020 – Ortho Dermatologics, one of the largest dermatology health care businesses in the world, today announced the presentation of nine posters during the virtual Fall Clinical Dermatology Conference, which takes place Oct. 29 – Nov. 1, 2020. The presentations will feature new post hoc analyses on ARAZLO™ (tazarotene) Lotion, 0.045%, DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, and SILIQ® (brodalumab) injection 210 mg/1.5 ml, as well as pediatric data on JUBLIA® (efinaconazole) topical solution, 10%. Please see below for warning about suicidal ideation and behavior with SILIQ.
July 28, 2020
ORTHO DERMATOLOGICS ANNOUNCES 2020 ASPIRE HIGHER SCHOLARSHIP RECIPIENTS
Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

RALEIGH, N.C., July 27, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship up to $10,000 to pursue their undergraduate or graduate degrees.

“At Ortho Dermatologics, we know that the physical and emotional burden of living with a skin condition can make it difficult for students to manage their academics and extracurricular activities,” said Bill Humphries, president, Ortho Dermatologics. “We are proud to continue the Aspire Higher scholarship program to help students affected by dermatologic conditions reach their educational goals, while also celebrating the positive impact dermatologists and health care professionals have had on their lives.”
June 23, 2020
ORTHO DERMATOLOGICS ANNOUNCES ARAZLO™ (TAZAROTENE) LOTION, 0.045%, NOW AVAILABLE IN THE U.S.
ARAZLO™ (tazarotene) Lotion, 0.045% is Indicated for the Topical Treatment of Acne Vulgaris in Patients Nine Years of Age and Older

RALEIGH, N.C., June 23, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that ARAZLO™ (tazarotene) Lotion, 0.045%, is available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration (FDA) in December 2019, ARAZLO is the first tazarotene acne treatment available in lotion formulation.
April 29, 2020
FDA APPROVES ORTHO DERMATOLOGICS’ LABELING FOR JUBLIA® (EFINACONAZOLE) TOPICAL SOLUTION, 10%, IN PATIENTS AS YOUNG AS SIX YEARS OLD
RALEIGH, N.C., April 29, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for JUBLIA® (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product’s label to children six years of age and older.1 JUBLIA was first approved in June 2014 in patients 18 years and older. “Onychomycosis is increasingly being seen in pediatrics – representing 15 percent of all nail dystrophies in children,”2 said Bill Humphries, president, Ortho Dermatologics. “With nearly six years of real-world use since its initial approval to treat adults in 2014, JUBLIA has a demonstrated safety and efficacy profile, and we are pleased the FDA has recognized it as a valuable treatment option for children with toenail fungal infections.”
February 18, 2020
ORTHO DERMATOLOGICS EXPANDS CASH-PAY PROGRAM, DERMATOLOGY.COM
RALEIGH, N.C., Feb. 18, 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced an expansion of Dermatology.com, the first and only non-reimbursed, cash-pay program in dermatology in the United States. Four products have been added to the program, which include RENOVA® (tretinoin cream 0.02%), LOPROX® shampoo (ciclopirox 1%), SOLODYN® (minocycline hydrochloride) extended release tablets and the program’s first over-the-counter option, BenzEFoam® (benzoyl peroxide emollient foam 5.3%/9.8%). A new telemedicine platform has also been added, offering patients the ability to consult with a health care professional, order and potentially receive a prescription on-demand for many of the branded dermatology products available in the program.1 Some products, such as SOLODYN® (minocycline hydrochloride) extended release tablets, EFUDEX® (fluorouracil) topical cream, 5%, and ALDARA® (imiquimod) cream, 5%, which are for more serious skin conditions, will require an in-office visit instead. “We launched Dermatology.com in March 2019 to provide physicians and patients access to proven, branded treatment options for certain disease states that typically encounter coverage hassles and challenges like acne and barrier repair,” said Bill Humphries, president, Ortho Dermatologics. “Now, with the telemedicine platform, the program is making it possible for patients to receive high-quality, well-known, FDA-approved treatments in a convenient, on-demand manner while, at the same time, ensuring patients are directed to see a board-certified dermatologist when their skin conditions require an in-office visit.”
February 3, 2020
ORTHO DERMATOLOGICS OPENS 2020 ASPIRE HIGHER SCHOLARSHIP PROGRAM
Students Treated for Dermatologic Conditions Can Apply for the Scholarship Through April 27, 2020 RALEIGH, N.C., Feb. 3 2020 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a $10,000 scholarship in support of their academic goals. “The role of a student today can be overwhelming – from managing their academics to extracurricular activities, work studies and more. Adding the physical and emotional burden of living with a skin condition, which is generally visible to see unlike other medical diseases, can make it even more difficult, which is why the relationship they have with their dermatologist is critically important to help them properly address their skincare needs,” said Bill Humphries, president, Ortho Dermatologics. “We remain committed to continuing the Aspire Higher program and look forward each year to providing more students who have been challenged by a skincare condition with the support they need to pursue their higher education.”
X
X
X